Restrictive Intraoperative Fluid Rate is Associated with Improved Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

被引:5
|
作者
Peng, June S. [1 ,2 ]
LaPiano, Jessica [3 ]
Wang, Katy [4 ]
Attwood, Kristopher [4 ]
Skitzki, Joseph J. [5 ]
Kane, John M., III [1 ]
Francescutti, Valerie A. [1 ,5 ]
机构
[1] Roswell Pk Comprehens Canc Ctr, Dept Surg Oncol, Buffalo, NY 14203 USA
[2] Penn State Univ, Div Surg Oncol, Coll Med, Dept Surg, Hershey, PA 16801 USA
[3] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[4] Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA
[5] McMaster Univ, Dept Surg, Hamilton, ON, Canada
关键词
MORBIDITY; THERAPY; TRIAL;
D O I
10.1245/s10434-021-10556-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Management of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) has historically favored liberal fluid administration owing to lengthy duration of surgery and hyperthermia. This practice has been challenged in recent years with studies demonstrating improved outcomes with restrictive fluid administration. Methods Patients who underwent CS/HIPEC between March 2010 and September 2018 were included for analysis. Patients who received an above-median fluid rate (high-IVF) versus below-median fluid rate (low-IVF) were compared, and multivariate analyses were performed for length of stay, 90-day unplanned readmissions, and major complications. Results The 167 patients had a mean age of 56.7 +/- 11.4 years and body mass index of 29.5 +/- 6.9 kg/m(2). The median rate of total intraoperative crystalloid and colloid was 7.4 mL/kg/h. The low-IVF group had less blood loss (183 vs. 330 mL, p = 0.002), were less likely to need intraoperative vasopressor drip (2.4% vs. 11.9%, p = 0.018), and experienced fewer cardiac complications (2.4% vs. 10.7%, p = 0.031), pneumonias (0% vs. 6.0%, p = 0.024), and Clavien-Dindo grade 3-5 complications (14.5% vs. 33.3%, p = 0.004). Multivariate analyses identified bowel resection (HR 4.65, p = 0.0008) as a risk factor for 90-day unplanned readmission, while bowel resection, intraoperative fluid rate, and estimated blood loss were associated with increased length of stay. Conclusion Higher intraoperative fluid intake was associated with multiple postoperative complications and increased length of stay, and represents a potentially avoidable risk factor for morbidity in CS/HIPEC.
引用
收藏
页码:163 / 173
页数:11
相关论文
共 50 条
  • [41] Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Zahid, A.
    Clarke, L.
    Carr, N.
    Chandrakumaran, K.
    Tzivanakis, A.
    Dayal, S.
    Mohamed, F.
    Cecil, T.
    Moran, B. J.
    BJS OPEN, 2021, 5 (02):
  • [42] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?
    Ingmar Knigsrainer
    Stefan Beckert
    World Journal of Gastroenterology, 2012, (38) : 5317 - 5320
  • [43] Minimally invasive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Altoukhi, Khaled H.
    Alzahrani, Nayef A.
    Morris, David L.
    ANNALS OF LAPAROSCOPIC AND ENDOSCOPIC SURGERY, 2018, 3
  • [44] Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Sarcomatosis
    Randle, Reese W.
    Swett, Katrina R.
    Shen, Perry
    Stewart, John H.
    Levine, Edward A.
    Votanopoulos, Konstantinos I.
    AMERICAN SURGEON, 2013, 79 (06) : 620 - 624
  • [45] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer
    Gronau, Felix
    Jara, Maximilian
    Feldbruegge, Linda
    Wolf, Vincent
    Oeff, Alan
    Rau, Beate
    CHIRURG, 2021, 92 (06): : 522 - 527
  • [46] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis
    Nesher, Eviatar
    Greenberg, Ron
    Avital, Shmuel
    Skornick, Yehuda
    Schneebaunn, Schlomo
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2007, 9 (11): : 787 - 790
  • [47] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer
    Ramakrishnan Ayloor Seshadri
    Olivier Glehen
    World Journal of Gastroenterology, 2016, (03) : 1114 - 1130
  • [48] Robotic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is there a benefit?
    Sparkman, Brian K.
    Freudenberger, Devon C.
    Vudatha, Vignesh
    Trevino, Jose G.
    Khader, Adam
    Fernandez, Leopoldo J.
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2025, 39 (01): : 513 - 521
  • [49] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer
    Newman, N. A.
    Votanopoulos, K. I.
    Stewart, J. H.
    Shen, P.
    Levine, E. A.
    MINERVA CHIRURGICA, 2012, 67 (04) : 309 - 318
  • [50] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?
    Koenigsrainer, Ingmar
    Beckert, Stefan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (38) : 5317 - 5320